News headlines about Adaptimmune Therapeutics (NASDAQ:ADAP) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adaptimmune Therapeutics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.6956637796764 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s scoring:
Several research analysts have recently issued reports on ADAP shares. Leerink Swann started coverage on shares of Adaptimmune Therapeutics in a research note on Friday, March 16th. They issued a “buy” rating and a $15.00 target price on the stock. BidaskClub upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. ValuEngine upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $11.58.
Shares of Adaptimmune Therapeutics stock opened at $12.36 on Tuesday. Adaptimmune Therapeutics has a twelve month low of $4.28 and a twelve month high of $13.41.
Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.04). The company had revenue of $4.27 million for the quarter, compared to the consensus estimate of $9.38 million. Adaptimmune Therapeutics had a negative net margin of 185.39% and a negative return on equity of 32.26%. analysts expect that Adaptimmune Therapeutics will post -0.82 earnings per share for the current year.
In related news, CFO Adrian Rawcliffe sold 600,000 shares of the stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $1.71, for a total transaction of $1,026,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Ravi Viswanathan acquired 104,844 shares of the stock in a transaction that occurred on Wednesday, March 21st. The shares were bought at an average price of $1.81 per share, for a total transaction of $189,767.64. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 9,385,254 shares of company stock worth $17,966,655. 24.45% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Adaptimmune Therapeutics (ADAP) Receives Daily Coverage Optimism Score of 0.12” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/17/adaptimmune-therapeutics-adap-receives-daily-coverage-optimism-score-of-0-12.html.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.